Literature DB >> 19037815

Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-up.

S Villar del Saz1, O Sued, V Falcó, F Agüero, M Crespo, T Pumarola, A Curran, J M Gatell, A Pahissa, J M Miró, E Ribera.   

Abstract

The objective of this study is to describe a series of cases of severe meningitis caused by human immunodeficiency virus type 1 (HIV-1) occurring during primary infection or after antiretroviral treatment interruption. In an observational cohort study, 13 patients with clinical diagnosis of meningitis or meningoencephalitis were reviewed. Ten cases occurred during primary HIV-1 infection and 3 after antiretroviral therapy (ART) withdrawal. Demographic parameters, clinical presentation and outcome, and laboratory and cerebrospinal fluid (CSF) parameters were recorded. The risk factor for HIV-1 infection acquisition was sexual transmission in all cases. The most frequent systemic symptoms were fever (12/13) and headeache (9/13). Among neurologic symptoms, focal signs appeared in seven patients (53.8%), confusion in six (46.2%), and agitation in five (38.5%). The median CD4 cell count was 434 cells/mm3. In all cases, CSF was a clear lymphocytaire fluid with normal glucose levels. Cranial computerized tomography was performed in seven patients, with a normal result in all of them; brain magnetic resonance in eight patients was normal in five cases and showing cortical atrophy, limbic encephalitis, and leptomeningeal enhancement in one patient each. The electroencephalographs (EEG) just showed diffuse dysfunction in three cases. ART was started in 11 patients. HIV RNA load at 12 months was <50 copies/ml in all treated patients. The 13 patients recovered without neurologic sequela. Meningitis or meningoencephalitis during primary HIV-1 infection or after ART cessation are unusual but sometimes a life-threatening manifestation. Although all patients tend to recover and the necessity of ART is not well established, some data suggest its potential benefit in these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19037815     DOI: 10.1080/13550280802195367

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  23 in total

1.  Acute HIV infection among patients tested for mononucleosis.

Authors:  E S Rosenberg; A M Caliendo; B D Walker
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

2.  Acute meningoencephalitis and meningitis due to primary HIV infection.

Authors:  P J Newton; W Newsholme; N S Brink; H Manji; I G Williams; R F Miller
Journal:  BMJ       Date:  2002-11-23

3.  Retroviral rebound syndrome with meningoencephalitis after cessation of antiretroviral therapy.

Authors:  Guillaume Breton; Xavier Duval; Anne Gervais; Pascale Longuet; Catherine Leport; Jean-Louis Vildé
Journal:  Am J Med       Date:  2003-06-15       Impact factor: 4.965

4.  Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy: implications for structured treatment interruptions.

Authors:  Michael G Worthington; John J Ross
Journal:  AIDS       Date:  2003-09-26       Impact factor: 4.177

5.  Activity of adenosine deaminase in cerebrospinal fluid for the diagnosis and follow-up of tuberculous meningitis in adults.

Authors:  E Ribera; J M Martinez-Vazquez; I Ocaña; R M Segura; C Pascual
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

6.  Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.

Authors:  Asa Mellgren; Andrea Antinori; Paola Cinque; Richard W Price; Christian Eggers; Lars Hagberg; Magnus Gisslén
Journal:  Antivir Ther       Date:  2005

7.  Acute human immunodeficiency virus infection.

Authors:  Shao-Tsung Huang; Hsin-Chun Lee; Kung-Hung Liu; Nan-Yao Lee; Wen-Chien Ko
Journal:  J Microbiol Immunol Infect       Date:  2005-02       Impact factor: 4.399

8.  Influence of neurologic manifestations of primary human immunodeficiency virus infection on disease progression. SEROCO Study Group.

Authors:  F Boufassa; C Bachmeyer; N Carré; C Deveau; A Persoz; C Jadand; D Séréni; D Bucquet
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

Review 9.  [Symptomatic primary human immunodeficiency virus infection].

Authors:  C Bachmeyer; G Grateau; D Sereni
Journal:  Rev Med Interne       Date:  1997       Impact factor: 0.728

10.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01
View more
  8 in total

Review 1.  Acute encephalitis - diagnosis and management.

Authors:  Mark Ellul; Tom Solomon
Journal:  Clin Med (Lond)       Date:  2018-03       Impact factor: 2.659

2.  Loss of neuronal integrity during progressive HIV-1 infection of humanized mice.

Authors:  Prasanta K Dash; Santhi Gorantla; Howard E Gendelman; Jaclyn Knibbe; George P Casale; Edward Makarov; Adrian A Epstein; Harris A Gelbard; Michael D Boska; Larisa Y Poluektova
Journal:  J Neurosci       Date:  2011-03-02       Impact factor: 6.167

3.  International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.

Authors: 
Journal:  J Int AIDS Soc       Date:  2016-10-23       Impact factor: 5.396

Review 4.  HIV, antiretroviral therapies, and the brain.

Authors:  Kevin J Liner; Michelle J Ro; Kevin R Robertson
Journal:  Curr HIV/AIDS Rep       Date:  2010-05       Impact factor: 5.071

Review 5.  Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy.

Authors:  Francesca Ferretti; Magnus Gisslen; Paola Cinque; Richard W Price
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

6.  Tissue-specific HIV-1 infection: why it matters.

Authors:  Maile Ay Karris; Davey M Smith
Journal:  Future Virol       Date:  2011-07       Impact factor: 1.831

7.  Neurological involvement in patients with acute/recent HIV-1 infection. A case-control study.

Authors:  Juan Ambrosioni; Francisca Artigues; David Nicolás; Judit Peñafiel; Fernando Agüero; Christian Manzardo; María Mar Mosquera; Sonsoles Sánchez-Palomino; Elisa De Lazzari; María A Marcos; Montserrat Plana; José M Miró
Journal:  J Neurovirol       Date:  2017-07-17       Impact factor: 3.739

8.  Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study.

Authors:  Alice Gravier-Dumonceau; Roxana Ameli; Veronique Rogemond; Anne Ruiz; Bastien Joubert; Sergio Muñiz-Castrillo; Alberto Vogrig; Geraldine Picard; Aditya Ambati; Marie Benaiteau; Florence Rulquin; Jonathan Ciron; Kumaran Deiva; Thomas de Broucker; Laurent Kremer; Philippe Kerschen; François Sellal; Bastien Bouldoires; Roxana Genet; Julien Biberon; Adrien Bigot; Fanny Duval; Nahema Issa; Elena-Camelia Rusu; Mathilde Goudot; Anais Dutray; Jean Louis Devoize; Lucie Hopes; Anne-Laure Kaminsky; Marion Philbert; Eve Chanson; Amelie Leblanc; Erwan Morvan; Daniela Andriuta; Philippe Diraison; Gabriel Mirebeau; Celine Derollez; Veronique Bourg; Quentin Bodard; Clementine Fort; Irina Grigorashvili-Coin; Guillaume Rieul; Daniela Molinier-Tiganas; Mickaël Bonnan; Thierry Tchoumi; Jérôme Honnorat; Romain Marignier
Journal:  Neurology       Date:  2021-11-19       Impact factor: 9.910

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.